13 results match your criteria: "Cytopathology NYC Health + Hospitals Bellevue[Affiliation]"
High-Consequence Infectious Diseases, Bioterrorism, and the Imperative for International and US Biosecurity and Biosafety Frameworks for Biocontainment Clinical Laboratories.
Health Secur
November 2024
Syra Madad, DHSc, MSc, MCP, CHEP, is Senior Director, System-Wide Special Pathogens Program, Emergency Management, NYC Health + Hospitals (H+H), New York, NY. Jessica L. Jacobson, MD, is Laboratory Director and Chief of Pathology, NYC H+H/Bellevue, and a Clinical Professor of Pathology, Department of Pathology, NYU Grossman School of Medicine; both in New York, NY. Rebecca R. Caruso, MPH, RBP, CBSP (ABSA), CAGS, is Director, Committee on Microbiological Safety, Harvard Medical School, Boston, MA. Jake Dunning, MBBS, MRCP, DIC, PhD, is a Consultant, Department of Infectious Diseases, Royal Free Hospital, London, and a Senior Research Fellow, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae.
JAMA Dermatol
July 2024
Wadsworth Center Mycology Laboratory, New York State Department of Health, Albany.
Importance: Trichophyton indotineae is an emerging dermatophyte causing outbreaks of extensive tinea infections often unresponsive to terbinafine. This species has been detected worldwide and in multiple US states, yet detailed US data on infections with T indotineae are sparse and could improve treatment practices and medical understanding of transmission.
Objective: To correlate clinical features of T indotineae infections with in vitro antifungal susceptibility testing results, squalene epoxidase gene sequence variations, and isolate relatedness using whole-genome sequencing.
A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment.
J Addict Med
June 2024
From the Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut (MGG, MB, CH, DTB); The APT Foundation, Inc., New Haven, Connecticut (MGG, ET, MB, LMM, CH, DTB); Department of Emergency Medicine, NYU Langone School of Medicine/NYC Health and Hospitals Bellevue, New York, New York (MGG); Department of Statistics, University of California at Berkeley, Berkeley, California (IDC); Department of Pathology and Laboratory Medicine, University of California at San Francisco School of Medicine, San Francisco, California (IDC); Rutgers New Jersey Medical School, Rutgers, New Jersey (ET); Department of Internal Medicine, Oregon Health and Science University, Portland OR (KH); Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut (LMM, GS); Child Study Center, Yale School of Medicine, New Haven, Connecticut (MB, DTB); and University of Jordan, Amman, Jordan (MH).
Background: Few studies have examined illness models among people with addiction. We investigated illness models and their associations with demographics and treatment beliefs among patients receiving methadone treatment for opioid use disorder.
Methods: From January 2019 to February 2020, patients receiving methadone treatment at outpatient opioid treatment programs provided demographics and rated using 1 to 7 Likert-type scales agreement with addiction illness models (brain disease model, chronic medical condition model [CMCM], and no explanation [NEM]) and treatment beliefs.
Red Blood Cell Transfusion: 2023 AABB International Guidelines.
JAMA
November 2023
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
Article Synopsis
- Red blood cell transfusions can be beneficial but come with potential risks, necessitating guidelines for their use in both adults and children.
- Studies involved numerous randomized controlled trials which found that restrictive transfusion strategies (transfusing at lower hemoglobin thresholds) generally do not harm patient outcomes for most populations.
- Recommendations include using restrictive strategies for stable adult patients, advising transfusions at hemoglobin levels below 7 g/dL, with some exceptions based on specific patient conditions like cardiac or orthopedic surgeries.
A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States.
Subst Abus
May 2023
APT Foundation, Inc., New Haven, CT, USA.
Background: Homelessness is an important social determinant of health (SDOH), impacting health outcomes for many medical conditions. Although homelessness is common among people with opioid use disorder (OUD), few studies systematically evaluate homelessness and other SDOH among people enrolled in standard of care treatment for OUD, medication for opioid use disorder (MOUD), or examine whether homelessness affects treatment engagement.
Methods: Using data from the 2016 to 2018 U.
Biography of George N. Papanicolaou, MD, PhD: Historical Variations of the Reported Wedding Date.
Acta Cytol
January 2023
CellPathology Plus, Richmond Hill, Ontario, Canada.
Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study.
Clin Infect Dis
August 2022
Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Coronavirus disease 2019 symptom definitions rarely include symptom severity. We collected daily nasal swab samples and symptom diaries from contacts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case patients. Requiring ≥1 moderate or severe symptom reduced sensitivity to predict SARS-CoV-2 shedding from 60.
View Article and Find Full Text PDFDelayed SARS-COV-2 leukoencephalopathy without Severe Hypoxia.
J Neurol Sci
November 2020
Department of Neurology, NYU Langone Medical Center, New York, NY 10016, United States of America; Department of Neurosurgery, NYU Langone Medical Center, New York, NY 10016, United States of America.
• A patient developed encephalopathy two months after a mild case of COVID-19. • MRI Brain demonstrated extensive white matter lesions juxtacortically and subcortically. • Workup for infectious, paraneoplastic, toxic process was negative.
View Article and Find Full Text PDFExosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
Stem Cells Dev
June 2020
Department of Anesthesiology, NYC Health + Hospitals/Bellevue, New York, New York, USA.
This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment.
View Article and Find Full Text PDFCytomegalovirus (CMV) in cervical cancer screening tests: A series of 8 cases and review of the literature.
Diagn Cytopathol
July 2018
NYU School of Medicine, Professor, Assistant Director, Cytopathology NYC Health + Hospitals Bellevue, Director, Anatomic Pathology, NYU Langone Health, 560 First Ave, New York, 10016, New York.
Objective: Cytomegalovirus (CMV) is a ubiquitous infection typically affecting over 50% of the US population by age 40. We report 8 cases of CMV infections detected in cervical cancer screening tests, the largest series of cases thus far reported in gynecologic cytology specimens.
Methods: A retrospective review of our pathology archival computer database was performed from January 1, 1994 through December 31, 2016 for CMV infections reported in cervical cytology specimens.
The National Ebola Training and Education Center: Preparing the United States for Ebola and Other Special Pathogens.
Health Secur
April 2018
Christopher J. Kratochvil, MD, is Associate Vice Chancellor for Clinical Research, University of Nebraska Medical Center, and Vice President for Research, Nebraska Medicine, Omaha, NE. Laura Evans, MD, MSc, is Associate Professor, Division of Pulmonary, Critical Care and Sleep Medicine, NYU School of Medicine, New York, NY. Bruce S. Ribner, MD, MPH, is Professor of Medicine, Emory University School of Medicine, and Medical Director, Serious Communicable Diseases Unit, Emory University Hospital, Atlanta, GA. John J. Lowe, PhD, is Associate Professor, Department of Environmental, Agricultural, and Occupational Health, University of Nebraska Medical Center, Omaha, NE. Melissa Cole Harvey, MSPH, is Director, and Richard C. Hunt, MD, MS, is Senior Medical Advisor, both in the Division of National Healthcare Preparedness Programs, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC. Abbigail J. Tumpey, MPH, is Associate Director for Communications Science, Center for Surveillance, Epidemiology, and Laboratory Services, and Ryan P. Fagan, MD, MPH&TM, is a Medical Officer, Division of Healthcare Quality Promotion, both at the Centers for Disease Control and Prevention, Atlanta, GA. Michelle M. Schwedhelm, MSN, is Executive Director, Infection Prevention & Emergency Preparedness, Nebraska Medicine, Omaha, NE. John Maher, JD, is Senior Director, Special Pathogens Program, NYC Health + Hospitals/Bellevue, New York, NY. Colleen S. Kraft, MD, MSc, is Associate Professor, Department of Pathology/Laboratory Medicine, Division of Infectious Diseases, and Sharon Vanairsdale, MS, APRN, is Program Director, Serious Communicable Diseases, both at Emory University Hospital, Atlanta, GA. Nicholas V. Cagliuso, Sr., PhD, MPH, is Assistant Vice President, Emergency Management, NYC Health + Hospitals, New York, NY. Angela Vasa, BSN, RN, CCRN, is Clinical Program Coordinator, Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE. Philip W. Smith, MD, is Emeritus Professor, College of Public Health, University of Nebraska Medical Center, Omaha, NE.
The National Ebola Training and Education Center (NETEC) was established in 2015 in response to the 2014-2016 Ebola virus disease outbreak in West Africa. The US Department of Health and Human Services office of the Assistant Secretary for Preparedness and Response and the US Centers for Disease Control and Prevention sought to increase the competency of healthcare and public health workers, as well as the capability of healthcare facilities in the United States, to deliver safe, efficient, and effective care to patients infected with Ebola and other special pathogens nationwide. NYC Health + Hospitals/Bellevue, Emory University, and the University of Nebraska Medical Center/Nebraska Medicine were awarded this cooperative agreement, based in part on their experience in safely and successfully evaluating and treating patients with Ebola virus disease in the United States.
View Article and Find Full Text PDFClosing the Brief Case: Anaerobiospirillum succiniciproducens Bacteremia and Pyomyositis.
J Clin Microbiol
March 2017
Department of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA.
The Brief Case: Anaerobiospirillum succiniciproducens Bacteremia and Pyomyositis.
J Clin Microbiol
March 2017
Department of Pathology, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA.